Zenas BioPharma (ZBIO) Long-Term Deferred Tax (2023 - 2026)
Zenas BioPharma's (ZBIO) quarterly Long-Term Deferred Tax came in at $439000.0 in Q1 2026, down 38.08% quarter-over-quarter from $709000.0 in Q4 2025.
Zenas BioPharma (ZBIO) Long-Term Deferred Tax (2023 - 2026) Analysis & Trends
Zenas BioPharma's Long-Term Deferred Tax history runs 3 years deep, the most recent figure standing at $439000.0 for Q1 2026.
- On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $439000.0 in Q1 2026; TTM through Mar 2026 was $439000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $709000.0, changed N/A from the prior year.
- Long-Term Deferred Tax retreated to $439000.0 in Q1 2026 per ZBIO's latest filing, from $709000.0 in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $1.4 million in Q4 2023 and bottomed at $439000.0 in Q1 2026.
- The 3-year median for Long-Term Deferred Tax is $773000.0 (2025), against an average of $846250.0.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Zenas BioPharma | 1.72 Bn | 1.72 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 439,000.00 |
| Dec 31, 2025 | 709,000.00 |
| Sep 30, 2025 | 837,000.00 |
| Dec 31, 2023 | 1.40 Mn |